3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Oropharyngeal Neoplasms
4
Head and Neck Neoplasms
3
Lung Neoplasms
2
Glioblastoma
2
Uterine Cervical Neoplasms
1
Tobacco Use Disorder
1
Thymoma
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Smoking Cessation
1
Smoking
1
Sinonasal Squamous Cell Carcinoma
1
Rectal Neoplasms
1
Rectal Malignant Neoplasms
1
Radiation Injuries
1
Postoperative Complications
1
Pathologic Complete Response
1
Papillomavirus Infections
1
Pancreatic Neoplasms
1
Mouth Neoplasms
1
Low Anterior Resection Syndrome
1
Laryngeal Neoplasms
1
Infiltrating Bladder Urothelial Carcinoma
1
HPV-Related Squamous Cell Carcinoma
1
Fatigue
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Interventions
Carboplatin
3
durvalumab
2
Tretinoin
2
Paclitaxel
2
Irinotecan
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
tegafur-gimeracil-oteracil
1
talazoparib
1
sarilumab
1
pexidartinib
1
pertuzumab
1
pembrolizumab
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
dostarlimab
1
cemiplimab
1
abemaciclib
1
Trastuzumab
1
Surgical Procedures, Operative
1
Standard of Care
1
STA 9090
1
SGN-LIV1A
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
Chemoradiotherapy
×
90 days
×
Clear all
NCT07472868
2026-03-16
MEND-IT II
Catharina Ziekenhuis Eindhoven
Phase 3
Not yet recruiting
394 enrolled